Thursday, August 9, 2012

ISO-1 by Al-Abed at Feinstein Institute

Quote:
Dr. Al-Abed developed a potent inhibitor of MIF [called ISO-1] that has been shown to be effective in preclinical studies of type 1 diabetes and sepsis, and is now designing clinical trials.